Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
05/2013
05/01/2013CN102180879B Polycrystalline type alpha acetic acid solvate of hypnotic
05/01/2013CN102174626B Method for preparing corn peptide
05/01/2013CN102058535B Novel folate receptor targeted liposome
05/01/2013CN102036976B Modulators of dopamine neurotransmission
05/01/2013CN102026643B The use and method of the compound of fasudil and the pharmaceutical composition thereof
05/01/2013CN101954107B Solid aromatic sleep aid and preparation method thereof
05/01/2013CN101821246B Tetrazole-substituted aryl amide derivatives and uses thereof
05/01/2013CN101810586B L-dopa methyl ester sustained-release microsphere composite and preparation method thereof
05/01/2013CN101679270B Dihydroquinone and dihydronaphthridine inhibitors of JNK
05/01/2013CN101664408B Stabilization of hypoxia inducible factor (HIF) alpha
05/01/2013CN101558057B 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders
05/01/2013CN101558038B Curcumin derivative
05/01/2013CN101554397B Applications of eucommia ulmoide total alkaloid
05/01/2013CN101495469B N-(aminoheteroaryl)-1H-indole-2-carboxamide derivatives as antagonist of TRPV1 or VR1 receptor, preparation thereof and therapeutic use thereof
05/01/2013CN101448831B Imidazo [1, 2-b] pyridazines, their processes of preparation and their use as GABA receptor ligands
05/01/2013CN101416976B External medicine composition preparation with anti-inflammation detumescence pain-easing function
05/01/2013CN101300005B N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
05/01/2013CN101282721B Composition for relieving subjective symptoms of fatigue
04/2013
04/30/2013USRE44186 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
04/30/2013US8431613 Memory fixation accelerator
04/30/2013US8431606 Medicament for treating schizophrenia comprising cilostazol
04/30/2013US8431589 2,4-diaminopyrimidine derivatives
04/30/2013US8431565 Substituted imidazoheterocycles
04/30/2013US8431159 Solid pharmaceutical dispersions with enhanced bioavailability
04/30/2013US8431121 Specifically targeted catalytic antagonists and uses thereof
04/30/2013CA2696948C 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
04/30/2013CA2589289C Use of (-)-1-(benzofuran-2-yl)-2-propylaminopentane to treat substance dependence
04/30/2013CA2584567C Pyrazolo (1,5-alpha) pyrimidinyl derivatives useful as corticotropin-releasing factor (crf) receptor antagonists
04/30/2013CA2579756C Modulators of central nervous system neurotransmitters
04/30/2013CA2571487C Pyrrazolo-pyrimidine derivatives
04/30/2013CA2570606C Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
04/25/2013WO2013059791A2 Methods and compositions for promoting axon regeneration and nerve function
04/25/2013WO2013059786A1 Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease
04/25/2013WO2013059449A1 Treatment of withdrawal symptoms to aid in nicotine use cessation with passiflora incarnata
04/25/2013WO2013059222A1 2-pyridyloxy-4-nitrile orexin receptor antagonists
04/25/2013WO2013059119A1 Glucosylceramide synthase inhibitors and therapeutic methods using the same
04/25/2013WO2013058681A2 Substituted phenoxyacetic acids and esters and amides thereof, comprising a 2,6-dioxo-2,3,6,7-tetrahydro-1н-purine-8-yl fragment and constituting а2a adenosine receptor antagonists, and the use thereof
04/25/2013WO2013058605A1 Pharmaceutical composition comprising fluoxetine as an active ingredient, for preventing or treating blood-brain barrier disorders
04/25/2013WO2013058303A1 Medicinal composition
04/25/2013WO2013058258A1 Bicyclic heterocyclic compound
04/25/2013WO2013057944A1 Novel spiroindoline compound, and medicinal agent comprising same
04/25/2013WO2013057554A2 Therapeutic combinations of netupitant and palonosetron
04/25/2013WO2013057322A1 (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
04/25/2013WO2013057222A2 Use of avermectin derivative for increasing bioavailability and efficacy of macrocylic lactones
04/25/2013WO2013057124A1 Solid forms of 1,l-dioxo-4-thiomorpholinyl)-[6-[[3(4-fluorophenyl)-5-methyl-4-isoxazolyl]methoxy]-3-pyridinyl]-methanone
04/25/2013WO2013056326A1 Controlled release pharmaceutical composition containing naltrexone and topiramate
04/25/2013WO2013030218A4 Selective and reversible inhibitors of ubiquitin specific protease 7
04/25/2013WO2013027986A3 Method of screening for chaperonin modulator
04/25/2013WO2013025474A9 Compositions and methods for regulating neutrophil movement and neutrophil numbers in a body region
04/25/2013WO2013025442A3 Concentrated felbamate formulations for parenteral administration
04/25/2013WO2013009981A9 Treating neurological disease or injury with a dynamin-related protein 1 (drp1) encoding nucleic acid
04/25/2013WO2012122340A8 Soluble guanylate cyclase activators
04/25/2013WO2012010974A8 Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
04/25/2013US20130102898 Liposome including elastin-like polypeptides and use thereof
04/25/2013US20130102690 Collagen-polysaccharide materials mimicking blood vessels, tissues and bones for medical, pharmaceutical and orthopedic applications, and processes for producing the same
04/25/2013US20130102619 2-pyridyloxy-4-nitrile orexin receptor antagonists
04/25/2013US20130102616 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
04/25/2013US20130102612 Topical dermal brimonidine compositions
04/25/2013US20130102584 Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
04/25/2013US20130102553 Therapeutic Strategies For Prevention And Treatment Of Alzheimer's Disease
04/25/2013US20130102544 Disease-Associated Proteins
04/25/2013US20130102073 Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
04/25/2013US20130101667 Cyclohexylamines
04/25/2013US20130101627 Composition with extracts from olive leaf, yarrow and rosemary for treating human diseases and conditions
04/25/2013US20130101610 Therapeutic Uses of CD137 in Treating Autoimmune Disease
04/25/2013US20130101601 Antibodies directed against nerve growth factor (ngf)
04/25/2013US20130101595 Antibodies that bind il-18 and methods of inhibiting il-18 activity
04/25/2013US20130101580 Compositions and methods for prolonging lifespan
04/25/2013US20130101577 Extended Soluble PH20 Polypeptides and uses thereof
04/25/2013US20130101565 Use of carbonic anhydrase ii for producing a drug
04/25/2013US20130101557 Recombinant Adenovirus Having Anti-Angiogenesis Activity
04/25/2013US20130101510 Methods of treating parkinson's disease using viral vectors
04/25/2013US20130098377 Excipients for nicotine-containing therapeutic compositions
04/25/2013US20130098357 Cerivastatin to treat pulmonary disorders
04/25/2013DE112011102362T5 Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit neurodegenerativen Erkrankungen in Verbindung stehen A pharmaceutical combination composition and methods for treating diseases or conditions associated with neurodegenerative diseases in connection
04/25/2013CA2852618A1 Pharmaceutical composition
04/25/2013CA2852607A1 Use of avermectin derivative for increasing bioavailability and efficacy of macrocylic lactones
04/25/2013CA2852469A1 Codon signature for neuromyelitis optica
04/25/2013CA2852425A1 2-pyridyloxy-4-nitrile orexin receptor antagonists
04/25/2013CA2852268A1 Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
04/25/2013CA2851589A1 Bicyclic heterocyclic compound
04/25/2013CA2850441A1 Solid forms of 1,l-dioxo-4-thiomorpholinyl)-[6-[[3(4-fluorophenyl)-5-methyl-4-isoxazolyl]methoxy]-3-pyridinyl]-methanone
04/25/2013CA2849564A1 (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
04/24/2013EP2583963A1 Proline analogs as ligands for cannabinoid receptors for the treatment of pain
04/24/2013EP2583692A1 Inhibitor of expression of dominant allele
04/24/2013EP2583687A1 Use of botulinum toxin for treating hyperhydrosis
04/24/2013EP2582832A1 Methods and pharmaceutical compositions for treating the animal central nervous system for psychiatric disorders
04/24/2013EP2582705A1 Anellated pyridine compounds as dual modulators of the 5-ht2a and d3 receptors
04/24/2013EP2582704A2 Asenapine maleate
04/24/2013EP2582676A1 Tetrahydroquinoline amide m1 receptor positive allosteric modulators
04/24/2013EP2582666A2 Aryl substituted indoles and their use as blockers of sodium channels
04/24/2013EP2582393A1 Dose selection of adjuvanted synthetic nanocarriers
04/24/2013EP2582375A2 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease
04/24/2013EP2582374A2 Methods for treating neurological conditions
04/24/2013EP2582368A1 Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
04/24/2013EP2343275B1 Crystalline form of the optical enantiomers of modafinil
04/24/2013CN1935141B Use of descarboethoxyloratadine or its pharmaceutical salts in preparing medicine for treating urticaria
04/24/2013CN1922320B Antisense compounds targeted to connexins and methods of use thereof
04/24/2013CN1726915B Nasal cavity drug delivery system and combination of naloxone hydrochloride and preparation method
04/24/2013CN1653050B Opioid and opioid-like compounds and uses thereof